JP2015514062A5 - - Google Patents

Download PDF

Info

Publication number
JP2015514062A5
JP2015514062A5 JP2015500673A JP2015500673A JP2015514062A5 JP 2015514062 A5 JP2015514062 A5 JP 2015514062A5 JP 2015500673 A JP2015500673 A JP 2015500673A JP 2015500673 A JP2015500673 A JP 2015500673A JP 2015514062 A5 JP2015514062 A5 JP 2015514062A5
Authority
JP
Japan
Prior art keywords
agent
cadherin
fragment
secad
inhibits
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015500673A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015514062A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/032656 external-priority patent/WO2013138790A1/en
Publication of JP2015514062A publication Critical patent/JP2015514062A/ja
Publication of JP2015514062A5 publication Critical patent/JP2015514062A5/ja
Pending legal-status Critical Current

Links

JP2015500673A 2012-03-15 2013-03-15 Ｅ−カドヘリンの細胞外ドメインの阻害剤を含む併用療法 Pending JP2015514062A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261611390P 2012-03-15 2012-03-15
US61/611,390 2012-03-15
US201261736475P 2012-12-12 2012-12-12
US61/736,475 2012-12-12
PCT/US2013/032656 WO2013138790A1 (en) 2012-03-15 2013-03-15 Combination therapies including inhibitors of the extracellular domain of e-cadherin

Publications (2)

Publication Number Publication Date
JP2015514062A JP2015514062A (ja) 2015-05-18
JP2015514062A5 true JP2015514062A5 (https=) 2016-05-12

Family

ID=49161879

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015500673A Pending JP2015514062A (ja) 2012-03-15 2013-03-15 Ｅ−カドヘリンの細胞外ドメインの阻害剤を含む併用療法

Country Status (8)

Country Link
US (2) US20150037354A1 (https=)
EP (1) EP2844270A4 (https=)
JP (1) JP2015514062A (https=)
KR (1) KR20140138956A (https=)
CN (1) CN104519899A (https=)
CA (1) CA2867456A1 (https=)
RU (1) RU2014141114A (https=)
WO (1) WO2013138790A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014043633A1 (en) * 2012-09-17 2014-03-20 Agios Pharmaceuticals, Inc. Use of e-cadherin and vimentin for selection of treatment responsive patients
SG11201504022RA (en) 2012-11-21 2015-06-29 Agios Pharmaceuticals Inc Glutamase inhibitors and method of use
WO2014079011A1 (en) 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Heterocyclic compounds for inhibiting glutaminase and their methods of use
US9029531B2 (en) 2012-11-22 2015-05-12 Agios Pharmaceuticals, Inc. Compounds and their methods of use
US10000479B2 (en) 2014-03-21 2018-06-19 Agios Pharmaceuticals, Inc. Compounds and their methods of use
KR102486321B1 (ko) * 2014-07-18 2023-01-09 사노피 암을 앓고 있는 것으로 의심되는 환자를 아플리베르셉트로 치료한 결과를 예측하는 방법
CN111208283B (zh) * 2018-11-21 2023-09-26 中国科学院分子细胞科学卓越创新中心 增效的肿瘤抑制组合物及其应用
CN115040695B (zh) * 2021-03-09 2023-10-13 南开大学 一种基于VE-cad-Fc/N-cad-Fc的融合蛋白活性界面的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT414097B (de) * 2004-06-25 2006-09-15 Petzelbauer Peter Dr Pharmazeutische zubereitung zur behandlung von schock
US8455249B2 (en) * 2009-05-01 2013-06-04 The University Of Tokyo Highly effective anti-cadherin antibody for induction of antibody-dependent cellular cytotoxicity in vivo
EP2632489B1 (en) * 2010-10-27 2020-01-15 The Research Foundation for The State University of New York Compositions targeting the soluble extracellular domain of e-cadherin and related methods for cancer therapy

Similar Documents

Publication Publication Date Title
JP2015514062A5 (https=)
US10966985B2 (en) Macrocyclic compounds as ROS1 kinase inhibitors
Qin et al. CTHRC1 promotes wound repair by increasing M2 macrophages via regulating the TGF-β and notch pathways
JP2009235074A (ja) 非機能性ｐ２ｘ７レセプター抗体、癌及びその他の容態の診断及び処理
RU2013123792A (ru) Композиции, нацеленные на растворимый внеклеточный домен е-кадгерина, и связанные с ними способы лечения онкологических заболеваний
RU2014141114A (ru) Комбинированные виды терапии с использованием ингибиторов внеклеточного домена е-кадгерина
BR112020020273A2 (pt) Inibidor de ret para uso no tratamento de câncer tendo uma alteração de ret
JP2013083665A (ja) 黒色腫における治療応答のための早期指標としての黒色腫阻害性活性（ｍｉａ）タンパク質の使用
WO2010120592A1 (en) Combination therapy using an anti-egfr agent(s) and igf-1r specific inhibitors
CN105873950A (zh) 用于治疗和诊断癌症的抗s100a7抗体
US20220056123A1 (en) Use of il-1beta binding antibodies
CN109709335B (zh) 热休克蛋白hspa4在肿瘤转移预测、预后评估和治疗中的应用
TWI842966B (zh) 一種具緩解抗癌藥物抗藥性及增加抗癌藥物敏感性之醫藥組合物及其用途
WO2016065877A1 (zh) Cd166作为肝癌诊断血清标志物的应用及其试剂盒
TWI517852B (zh) 微小ＲＮＡ ｍｉＲ－１９９ａ－５ｐ之用途
CN115175678B (zh) 使用btk抑制剂及其组合治疗dlbcl的方法
CN119997973A (zh) 使用间充质上皮转化因子（met）靶向剂治疗非小细胞肺癌的方法
Sachdev et al. 506 Phase (Ph) 1/2a study of TSR-011, a potent inhibitor of ALK and TRK, in advanced solid tumors including crizotinib-resistant ALK positive non-small cell lung cancer
JPWO2020243442A5 (https=)
Shi et al. Crizotinib attenuates bleomycin-induced pulmonary fibrosis via regulating fibroblast activation
Smithberger Kinome-Guided Development of Precision-Targeted Therapeutics for Glioblastoma
CN105879033A (zh) GnRH II型拮抗剂在抑制孕激素耐药子宫内膜癌细胞增殖中的应用
CN118354772A (zh) 治疗头颈癌的方法
EP4652199A1 (en) Anti-cd19 binding agents for the treatment and prevention of immune mediated necrotizing myopathy
EP4724150A1 (en) A 1,5-dihydro-4h-pyrrolo[3,2-c] pyridin-4-one for use in the treatment of cancer